These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38851877)

  • 1. CarcSeq detection of lorcaserin-induced clonal expansion of Pik3ca H1047R mutants in rat mammary tissue.
    Faske JB; Myers MB; Bryant M; He X; McLellen F; Bourcier T; Parsons BL
    Toxicol Sci; 2024 Jun; ():. PubMed ID: 38851877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia.
    McKim KL; Myers MB; Harris KL; Gong B; Xu J; Parsons BL
    Toxicol Sci; 2021 Jul; 182(1):142-158. PubMed ID: 33822199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia.
    Harris KL; McKim KL; Myers MB; Gong B; Xu J; Parsons BL
    Toxicol Sci; 2021 Oct; 184(1):1-14. PubMed ID: 34373914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq.
    Harris KL; Walia V; Gong B; McKim KL; Myers MB; Xu J; Parsons BL
    Environ Mol Mutagen; 2020 Nov; 61(9):872-889. PubMed ID: 32940377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
    Myers MB; McKim KL; Banda M; George NI; Parsons BL
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30813596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
    Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL
    Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
    PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
    Parsons BL; McKim KL; Myers MB
    Environ Mol Mutagen; 2017 Aug; 58(7):466-476. PubMed ID: 28755461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
    BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
    Meyer DS; Koren S; Leroy C; Brinkhaus H; Müller U; Klebba I; Müller M; Cardiff RD; Bentires-Alj M
    Oncogenesis; 2013 Sep; 2(9):e74. PubMed ID: 24080956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the discriminative stimulus effects of lorcaserin in rats.
    Serafine KM; Rice KC; France CP
    J Exp Anal Behav; 2016 Sep; 106(2):107-16. PubMed ID: 27640338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor.
    Kim SH; Seung BJ; Cho SH; Lim HY; Bae MK; Sur JH
    Animals (Basel); 2021 Jul; 11(7):. PubMed ID: 34359206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
    Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE
    J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.